Published in J Drug Target on February 01, 2008
Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm (2008) 1.39
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond) (2012) 1.14
Structure-activity relationships of cationic shell-crosslinked knedel-like nanoparticles: shell composition and transfection efficiency/cytotoxicity. Biomaterials (2009) 1.11
Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J Control Release (2014) 1.03
N-Alkyl-PEI-functionalized iron oxide nanoclusters for efficient siRNA delivery. Small (2011) 0.97
Phospholipid-polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery. Drug Deliv Transl Res (2011) 0.92
Highly PEGylated DNA Nanoparticles Provide Uniform and Widespread Gene Transfer in the Brain. Adv Healthc Mater (2015) 0.85
Structural and functional consequences of poly(ethylene glycol) inclusion on DNA condensation for gene delivery. Microsc Res Tech (2010) 0.84
Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound. J Control Release (2015) 0.84
Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. Int J Nanomedicine (2012) 0.82
Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agent. Bioorg Med Chem (2011) 0.82
Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev (2016) 0.82
Hypoxia-targeted siRNA delivery. Angew Chem Int Ed Engl (2014) 0.81
Toward personalized cancer nanomedicine - past, present, and future. Integr Biol (Camb) (2013) 0.80
PEI-complexed LNA antiseeds as miRNA inhibitors. RNA Biol (2012) 0.79
Highly compacted pH-responsive DNA nanoparticles mediate transgene silencing in experimental glioma. J Mater Chem B Mater Biol Med (2014) 0.77
Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma. Pharmaceuticals (Basel) (2011) 0.75
Polymer nanoassemblies with hydrophobic pendant groups in the core induce false positive siRNA transfection in luciferase reporter assays. Int J Pharm (2017) 0.75
MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res (2011) 1.79
RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther (2006) 1.65
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm (2010) 1.49
A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J Control Release (2006) 1.37
The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer (2007) 1.36
Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem (2002) 1.25
Poly(vinyl alcohol) nanofibers by electrospinning as a protein delivery system and the retardation of enzyme release by additional polymer coatings. Biomacromolecules (2005) 1.22
In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol (2009) 1.21
Retracted Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol (2003) 1.19
HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer (2008) 1.13
In vitro MR imaging of regulated gene expression. Radiology (2003) 1.12
Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. J Biol Chem (2003) 1.11
Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials (2010) 1.09
The fibroblast growth factor-binding protein FGF-BP. Int J Biochem Cell Biol (2005) 1.03
Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med (2010) 1.01
RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol (2011) 0.99
Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia (2009) 0.97
Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma. Neoplasia (2013) 0.94
Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol (2010) 0.94
Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas. J Neuropathol Exp Neurol (2003) 0.94
Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence. EMBO Mol Med (2013) 0.92
Physicochemical and biological characterization of polyethylenimine-graft-poly(ethylene glycol) block copolymers as a delivery system for oligonucleotides and ribozymes. Bioconjug Chem (2004) 0.91
Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.91
Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo. Methods Mol Biol (2010) 0.90
Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int J Cancer (2005) 0.90
Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery. Eur J Pharm Biopharm (2008) 0.89
Effects on neurite outgrowth and cell survival of a secreted fibroblast growth factor binding protein upregulated during spinal cord injury. Am J Physiol Regul Integr Comp Physiol (2007) 0.89
Inhibition of endogenous carcinoembryonic antigen (CEA) increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth. Clin Exp Metastasis (2002) 0.89
Retracted Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene (2003) 0.89
Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis. Cancer Res (2003) 0.88
MicroRNAs (miRNAs) in colorectal cancer: from aberrant expression towards therapy. Curr Pharm Des (2013) 0.88
Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun (2004) 0.86
Critical role of G(alpha)12 and G(alpha)13 for human small cell lung cancer cell proliferation in vitro and tumor growth in vivo. Clin Cancer Res (2010) 0.86
Multiple effects of the special AT-rich binding protein 1 (SATB1) in colon carcinoma. Int J Cancer (2014) 0.85
Differential regulation of a fibroblast growth factor-binding protein during skin carcinogenesis and wound healing. Neoplasia (2004) 0.85
Analysis of transcriptional regulation of the human miR-17-92 cluster; evidence for involvement of Pim-1. Int J Mol Sci (2013) 0.85
A sensitive polymerase chain reaction-based method for detection and quantification of metastasis in human xenograft mouse models. Clin Exp Metastasis (2010) 0.84
In vitro cytotoxic and immunomodulatory profiling of low molecular weight polyethylenimines for pulmonary application. Toxicol In Vitro (2009) 0.84
Efficiency of polyethylenimines and polyethylenimine-graft-poly (ethylene glycol) block copolymers to protect oligonucleotides against enzymatic degradation. Eur J Pharm Biopharm (2004) 0.84
Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.83
Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): Physicochemical and biological properties of DNA and siRNA complexes. J Control Release (2010) 0.83
Stimulation of the chemosensory TRPA1 cation channel by volatile toxic substances promotes cell survival of small cell lung cancer cells. Biochem Pharmacol (2012) 0.83
Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochem Cell Biol (2001) 0.83
U1 adaptors for the therapeutic knockdown of the oncogene pim-1 kinase in glioblastoma. Nucleic Acid Ther (2013) 0.81
Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene (2002) 0.80
Stabilization of oligonucleotide-polyethylenimine complexes by freeze-drying: physicochemical and biological characterization. J Control Release (2004) 0.80
The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival. EMBO Mol Med (2013) 0.79
PEI-complexed LNA antiseeds as miRNA inhibitors. RNA Biol (2012) 0.79
Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma. Mol Cancer (2011) 0.78
Hyperbranched PEI with various oligosaccharide architectures: synthesis, characterization, ATP complexation, and cellular uptake properties. Biomacromolecules (2009) 0.78
Nonviral delivery platform for therapeutic RNAi: pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2. Future Oncol (2009) 0.77
Therapeutic targeting of the mitotic spindle checkpoint through nanoparticle-mediated siRNA delivery inhibits tumor growth in vivo. Cancer Lett (2011) 0.77
Biocompatibility and efficacy of oligomaltose-grafted poly(ethylene imine)s (OM-PEIs) for in vivo gene delivery. Mol Pharm (2013) 0.77
Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics. Cancer Chemother Pharmacol (2014) 0.77
Tau silencing by siRNA in the P301S mouse model of tauopathy. Curr Gene Ther (2014) 0.76
The chorioallantoic membrane assay is a promising ex vivo model system for the study of vascular anomalies. In Vivo (2013) 0.75
Degradable and biocompatible poly(N,N-dimethylaminoethyl methacrylate-co-caprolactone)s as DNA transfection agents. Macromol Biosci (2013) 0.75
A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib. Eur J Pharm Biopharm (2013) 0.75
Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene (2005) 0.75
Polymer-based delivery of RNA-based therapeutics in ovarian cancer. Methods Mol Biol (2013) 0.75
A novel method for the assessment of targeted PEI-based nanoparticle binding based on a static surface plasmon resonance system. Anal Chem (2013) 0.75